The Cambridge spinout has raised $15m in series A funding from investors including Cambridge Enterprise and Parkwalk Advisors.
Cambridge Enterprise, the tech transfer office of University of Cambridge, co-led an £11m ($15m) series A round today for its UK-based biopharmaceutical spinout PhoreMost.
The round was co-led by spinout-focused investment firm Parkwalk Advisors, Amadeus Capital Partners, Morningside Ventures and Jonathan Milner.
PhoreMost has created a platform called Siteseeker to develop treatments for diseases that are currently deemed undruggable.
The company has built a pipeline, signed two collaboration agreements with pharmaceutical firms and, in November 2017, established cancer immunotherapy spinout…